DRUG · Mapped RxNorm record
Ixazomib
Normalized identity: ixazomib View linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
NCT03236792
Study summary
ClinicalTrials.govIxazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Cyclophosphamide
Normalized identity: cyclophosphamide View linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Dexamethasone
Normalized identity: dexamethasone View linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
AL Amyloidosisverified · MONDO: AL amyloidosis
Interventions
IxazomibDRUG · verified · RxNorm: ixazomib
CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
DexamethasoneDRUG · verified · RxNorm: dexamethasone
Sponsors & collaborators
Icahn School of Medicine at Mount Sinailead sponsor
Millennium Pharmaceuticals, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03236792 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.